@misc{oai:niigata-u.repo.nii.ac.jp:00032062,
 author = {Kudo, Risa},
 month = {Mar},
 note = {Background. Proactive recommendations for human papillomavirus (HPV) vaccines in Japan have been suspended for 5 years because of safety concerns. While no scientific evidence exists to substantiate these concerns, one reason given for not reinstating recommendations is the lack of reliable vaccine effectiveness (VE) data in a Japanese population. This study reports the VE of the bivalent HPV vaccine in Japanese women aged 20–22 years.
　Methods. During cervical screening between 2014 and 2016, women had Papanicolaou smears and HPV tests performed and provided data about their sexual history. Estimates of VE for vaccine-targeted HPV type 16 (HPV16) and 18 and cross-protection against other types were calculated.
　Results. Overall, 2197 women were tested, and 1814 were included in the analysis. Of these, 1355 (74.6%) were vaccinated, and 1295 (95.5%) completed the 3-dose schedule. In women sexually naive at vaccination, the pooled VEs against HPV16 and 18 and for HPV31, 45, and 52 were 95.5% (P < .01) and 71.9% (P < .01), respectively. When adjusted for number of sex partners and birth year, pooled VEs were 93.9% (P = .01) and 67.7% (P = .01) for HPV16 and 18 and HPV31, 45, and 52, respectively.
　Conclusions. The bivalent HPV vaccine is highly effective against HPV16 and 18. Furthermore, significant cross-protection against HPV31, 45, and 52 was demonstrated and sustained up to 6 years after vaccination. These findings should reassure politicians about the VE of bivalent HPV vaccine in a Japanese population., 学位の種類: 博士（医学）. 報告番号: 甲第4527号. 学位記番号: 新大院博（医）甲第849号. 学位授与年月日: 平成31年3月25日, 新大院博（医）甲第849号},
 title = {Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population : High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection},
 year = {2019}
}